Antithrombotic therapy in peripheral artery disease - Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines

Chest

Volumn 141, Issue 2 SUPPL., 2012, Pages e669S-e690S

  Alonso Coello, Pablo ^a   Bellmunt, Sergi ^b   McGorrian, Catherine ^c   Anand, Sonia S ^d   Guzman, Randolph ^e   Criqui, Michael H ^f   Akl, Elie A ^g   Vandvik, Per Olav ^h   Lansberg, Maarten G ⁱ   Guyatt, Gordon H ^d   Spencer, Frederick A ^j  

^a CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

^h INNLANDET HOSPITAL TRUST   (Norway)

ⁱ STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^j MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; HEPARIN; INDOBUFEN; NADROPARIN; PENTOXIFYLLINE; PHENPROCOUMON; PLACEBO; PROSTAGLANDIN DERIVATIVE; PROSTANOID; STREPTOKINASE; TICLOPIDINE; UROKINASE; WARFARIN;

AMPUTATION; ANKLE BRACHIAL INDEX; ANTICOAGULATION; ATTRIBUTABLE RISK; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CLAUDICATION; CORONARY STENT; DIARRHEA; DRUG INDUCED HEADACHE; ENDOVASCULAR SURGERY; FLUSHING; GRAFT PATENCY; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; INTERNATIONAL NORMALIZED RATIO; KINESIOTHERAPY; LIMB ISCHEMIA; LIMB SALVAGE; MORTALITY; NAUSEA; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RESTENOSIS; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; SMOKING CESSATION; STROKE; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; THROMBOSIS PREVENTION; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84856787115     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-2307     Document Type: Article

References (86)

1. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741-1750.
2. MacLean S, Mulla S, Akl EA, et al. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e1S-e23S.
3. Guyatt GH, Norris SL, Schulman S, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):50S-67S.
4. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2011;141(2)(suppl):e637S-e668S.
5. Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ. 1996;313(7070):1440-1444. (Pubitemid 26408032)
6. Newman AB, Shemanski L, Manolio TA, et al The Cardiovascular Health Study Group. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19(3):538-545. (Pubitemid 29135153)
7. Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation. 2004;109(6):733-739. (Pubitemid 38222892)
8. Ogren M, Hedblad B, Isacsson SO, Janzon L, Jungquist G, Lindell SE. Non-invasively detected carotid stenosis and ischaemic heart disease in men with leg arteriosclerosis. Lancet. 1993;342(8880):1138-1141. (Pubitemid 23324054)
9. van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation. 2004; 109(9):1089-1094. (Pubitemid 38332611)
10. Fowkes FG, Murray GD, Butcher I, et al Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300(2):197-208. (Pubitemid 351969304)
11. Baigent C, Blackwell L, Collins R, et al Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-1860.
12. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31-41.
13. Raju NC, Sobieraj-Teague M, Hirsh J, O'Donnell M, Eikelboom J. Effect of aspirin mortality in primary prevention of cardiovascular disease. Am J Med. 2011;124(7):621-6329.
14. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ. 2010;340:c117.
15. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet. 1996;348:1329-1339.
16. Sudlow CL, Mason G, Maurice JB, Wedderburn CJ, Hankey GJ. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev. 2009;(4):CD001246.
17. Keller TT, Squizzato A, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev. 2007;(3):CD005158.
18. Bhatt DL, Fox KA, Hacke W, et al CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717.
19. Johnson WC, Williford WO;Department of Veterans Affairs Cooperative Study #362. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant ther apy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg. 2002;35(3):413-421. (Pubitemid 44718584)
20. Sarac TP, Huber TS, Back MR, et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg. 1998;28(3):446-457. (Pubitemid 28421716)
21. Anand S, Yusuf S, Xie C, et al Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357(3):217-227. (Pubitemid 47080386)
22. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med. 1999;159(4):337-345. (Pubitemid 29091621)
23. Jonason T, Bergström R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987;221(3):253-260. (Pubitemid 17069424)
24. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. 1995;274(12):975-980.
25. Furukawa TA. From effect size into number needed to treat. Lancet. 1999;353(9165):1680. (Pubitemid 29224535)
26. Thorlund K, Walter S, Johnston B, Furukawa TA, Guyatt G. Pooling health-related quality of life outcomes in meta-analysis - a tutorial and review of methods for enhancing interpretability. Research Synthesis Methods. 2011.
27. Tamhane U, Meier P, Chetcuti S, et al. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. EuroIntervention. 2009;5(3):384-393.
28. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev. 2008;(1):CD003748.
29. Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R. Cilostazol, Naftidrofuryl Oxalate, Pentoxifylline, and Inositol Nicotinate for Intermittent Claudication in People With Peripheral Arterial Disease. London, England: National Institute for Health and Clinical Excellence; 2011:1-252.
30. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008;47(2):330-336.
31. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159(17):2041-2050. (Pubitemid 29453592)
32. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998;27(2):267-274, discussion 274-275.
33. Strandness DE Jr, Dalman RL, Panian S, et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovascular Surg. 2002;36(2):83-91. (Pubitemid 35278404)
34. O'Donnell ME, Badger SA, Sharif MA, Young IS, Lee B, Soong CV. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg. 2009;49(5):1226-1234.
35. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109(7):523-530.
36. Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol. 2001;87(12A):28D-33D.
37. Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev. 2001;(3):CD001999.
38. Antonicelli R, Sardina M, Scotti A, Bonizzoni E, Paciaroni E; Italian CAP Study Group. Randomized trial of the effects of low-dose calcium-heparin in patients with peripheral arterial disease and claudication. Am J Med. 1999;107(3):234-239. (Pubitemid 29421589)
39. Tesi M, Bronchi GF, Carini A, Morfini M, Cinotti S, Filiberti E. Efficacy and safety of a new low molecular weight heparin in the medium term treatment of atherosclerotic arteriopathy of the lower limbs. J Drug Dev. 1989;2 (2):73-82. (Pubitemid 19195471)
40. Calabrò A, Piarulli F, Milan D, Rossi A, Coscetti G, Crepaldi G. Clinical assessment of low molecular weight heparin effects in peripheral vascular disease. Angiology. 1993;44(3):188-195. (Pubitemid 23063858)
41. Mannarino E, Pasqualini L, Innocente S, et al. Efficacy of low-molecular-weight heparin in the management of intermittent claudication. Angiology. 1991;42(1):1-7.
42. Palmieri G, Ambrosi G, Agrati AM, Ferraro G, Marcozzi S. A new low molecular weight heparin in the treatment of peripheral arterial disease. Int Angiol. 1988;7(3 suppl):41-47. (Pubitemid 18267975)
43. Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg. 2009; 38(4):463- 474.
44. Ruffolo AJ, Romano M, Ciapponi A. Prostanoids for critical limb ischaemia. Cochrane Database Syst Rev. 2010;(1):CD006544.
45. Walker TG. Acute limb ischemia. Tech Vasc Interv Radiol.2009;12(2):117- 129.
46. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5-S67. (Pubitemid 46151680)
47. O'Connell JB, Quiñones-Baldrich WJ. Proper evaluation and management of acute embolic versus thrombotic limb ischemia. Semin Vasc Surg. 2009;22(1):10-16.
48. Berridge DC, Kessel D, Robertson I. Surgery versus thrombolysis for acute limb ischaemia: initial management. Cochrane Database Syst Rev. 2002;(3):CD002784
49. Ouriel K, Veith FJ, Sasahara AA; Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med. 1998;338(16):1105-1111. (Pubitemid 28227480)
50. Nilsson L, Albrechtsson U, Jonung T, et al. Surgical treatment versus thrombolysis in acute arterial occlusion: a randomised controlled study. Eur J Vasc Surg. 1992;6(2):189-193.
51. Ouriel K, Shortell CK, DeWeese JA, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg. 1994;19(6):1021-1030. (Pubitemid 24188096)
52. Ouriel K, Veith FJ, Sasahara AA;TOPAS Investigators. Thrombolysis or peripheral arterial surgery: phase I results. J Vasc Surg. 1996;23(1):64-75. (Pubitemid 26041478)
53. Weaver FA, Comerota AJ, Youngblood M, Froehlich J, Hosking JD, Papanicolaou G. Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. The STILE Investigators. Surgery versus Thrombolysis for Ischemia of the Lower Extremity. J Vasc Surg. 1996;24(4):513-523. (Pubitemid 26346615)
54. Robertson I, Kessel DO, Berridge DC. Fibrinolytic agents for peripheral arterial occlusion. Cochrane Database Syst Rev. 2010;(3):CD001099.
55. Berridge DC, Gregson RH, Hopkinson BR, Makin GS. Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis. Br J Surg. 1991;78(8):988-995.
56. Mahler F, Schneider E, Hess H;Steering Committee, Study on Local Thrombolysis. Recombinant tissue plasminogen activator versus urokinase for local thrombolysis of femoropopliteal occlusions: a prospective, randomized multicenter trial. J Endovasc Ther. 2001;8(6):638-647. (Pubitemid 34027742)
57. Meyerovitz MF, Goldhaber SZ, Reagan K, et al. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial. Radiology. 1990;175(1):75-78. (Pubitemid 20108543)
58. Schweizer J, Altmann E, Stösslein F, Florek HJ, Kaulen R. Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions. Eur J Radiol. 1996;22(2):129-132. (Pubitemid 26171965)
59. Dörffler-Melly J, Koopman MM, Prins MH, Büller HR. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev. 2005;(1):CD002071.
60. Heiss HW, Just H, Middleton D, Deichsel G. Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology. 1990;41(4):263-269. (Pubitemid 20164472)
61. Study Group on Pharmacological Treatment After TPA. Platelet inhibition with ASA/dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease. A prospective double-blind trial. Eur J Vasc Surg. 1994;8(1):83-88.
62. Do DD, Mahler F. Low-dose aspirin combined with dipyridamole versus anticoagulants after femoropopliteal percutaneous transluminal angioplasty. Radiology. 1994;193(2):567-571. (Pubitemid 24338353)
63. Pilger E, Lammer J, Bertuch H, et al. Nd:YAG laser with sapphire tip combined with balloon angioplasty in peripheral arterial occlusions. Long-term results. Circulation. 1991;83(1):141-147.
64. Schneider E. Rezidivprophylaxe nach perkutaner transluminaler Angioplastie (PTA):antikoagulation versus ticlopidin. In: Huber H, ed. Fortschritte in der Angiologie. Bern, Switzerland: Sage; 1987:355-356.
65. Schweizer J, Müller A, Forkmann L, Hellner G, Kirch W. Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty. Angiology. 2001;52(10):659-669. (Pubitemid 32963569)
66. Kasapis C, Henke PK, Chetcuti SJ, et al. Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30(1):44-55.
67. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study):a randomised trial. Lancet. 2000;355(9201):346-351.
68. Brown J, Lethaby A, Maxwell H, Wawrzyniak AJ, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev.2008;(4):CD000535.
69. Clyne CA, Archer TJ, Atuhaire LK, Chant AD, Webster JH. Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. Br J Surg. 1987;74(4):246-248. (Pubitemid 17051775)
70. Goldman M, McCollum C. A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vasc Surg. 1984;18 (4):217-221. (Pubitemid 14090432)
71. Donaldson DR, Salter MCP, Kester RC, et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts. Vasc Surg. 1985;19 (4):224-230. (Pubitemid 15003603)
72. Green RM, Roedersheimer LR, DeWeese JA. Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery. 1982;92(6):1016-1026. (Pubitemid 13083921)
73. Kohler TR, Kaufman JL, Kacoyanis G, et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery. 1984;96(3):462-466. (Pubitemid 14067491)
74. McCollum C, Alexander C, Kenchington G, Franks PJ, Greenhalgh R. Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial. J Vasc Surg. 1991;13(1):150-162.
75. Belch JJ, Dormandy J, Biasi GM, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52(4):825-833.
76. de Weerd M, Greving JP, Hedblad B, et al. Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis. Stroke. 2010;41(6):1294-1297.
77. Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2) (suppl):e601S-e636S.
78. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e326S-e350S.
79. Engelter S, Lyrer P. Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy. Cochrane Database Syst Rev. 2003;(3):CD001458.
80. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Part II: surgical group. Stroke. 1978;9(4):309-319. (Pubitemid 8364317)
81. Boysen G, Sørensen PS, Juhler M, et al. Danish very-lowdose aspirin after carotid endarterectomy trial. Stroke. 1988;19(10):1211-1215.
82. Kretschmer G, Pratschner T, Prager M, et al. Antiplatelet treatment prolongs survival after carotid bifurcation endarterectomy. Analysis of the clinical series followed by a controlled trial. Ann Surg. 1990;211(3):317-322. (Pubitemid 20105985)
83. Lindblad B, Persson NH, Takolander R, Bergqvist D. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial. Stroke. 1993;24(8):1125-1128. (Pubitemid 23237547)
84. Harker LA, Bernstein EF, Dilley RB, et al. Failure of aspirin plus dipyridamole to prevent restenosis after carotid endarterectomy. Ann Intern Med. 1992;116(9):731-736. (Pubitemid 23033116)
85. Pratesi C, Pulli R, Milanesi G, Lavezzari M, Pamparana F, Bertini D. Indobufen versus placebo in the prevention of restenosis after carotid endarterectomy: a double-blind pilot study. J Int Med Res. 1991;19(3):202-209.
86. Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet. 1999;353(9171):2179-2184. (Pubitemid 29295249)